Related Experiment Video

Updated: May 4, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.8K

Targeting Akt3 signaling in triple-negative breast cancer

Y Rebecca Chin1, Taku Yoshida, Andriy Marusyk

  • 1Authors' Affiliations: Department of Pathology, Beth Israel Deaconess Medical Center; Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; and Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Cancer Research
|December 17, 2013
PubMed

Insights

Researchers identified AKT3 as a key target for triple-negative breast cancer (TNBC). Inhibiting AKT3 significantly slows TNBC growth and may offer a new targeted therapy for this aggressive cancer subtype.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) lacks effective targeted therapies, leading to poor patient outcomes.
  • Identifying novel therapeutic targets is crucial for advancing TNBC treatment strategies.

Purpose of the Study:

  • To identify protein kinases as potential therapeutic targets in TNBC.
  • To investigate the specific role of AKT3 in TNBC growth and progression.

Main Methods:

  • Conducted a short hairpin RNA (shRNA) screen targeting protein kinases in breast cancer.
  • Utilized three-dimensional (3D) spheroid cultures and mouse xenograft models to assess TNBC growth.
  • Analyzed the effects of Akt3 downregulation on cell-cycle regulators and cell migration/invasion.

Main Results:

  • Identified AKT3 as a gene preferentially required for TNBC growth.
  • Downregulation of Akt3 significantly inhibited TNBC cell growth in vitro and in vivo.
  • Akt3 silencing upregulated the p27 cell-cycle inhibitor, which was critical for growth inhibition.
  • Akt3 depletion sensitized TNBC cells to the pan-Akt inhibitor GSK690693.

Conclusions:

  • AKT3 plays a specific and critical role in TNBC proliferation.
  • Targeting AKT3 presents a promising new therapeutic strategy for triple-negative breast cancer.
  • Further investigation into AKT3 inhibition could lead to effective treatments for TNBC.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K